Table 4.
Comparison between current study and prior CMR studies
| Study | Sample size | DAS | SJC | CRP, mg/l | Disease | α-TNF, % | Biologic, % | LGE, % or units | Native T1 | Location | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RA | Control | RA | Control | Duration | RA | Control | |||||||
| Current | 59 | 56 | 3.16 | 1 | 1.7 | 1.7 | 10 | 49% | 58% | 2% | 1 | No diff | USA |
| Ntusi20 | 39 | 39 | 3.3 | - | 9 | 1 | 7 | 0% | 5% | 46% | 0 | ↑RA | UK |
| Holmstrom21* | 31, 29 | 21 | 3.9, 3.7 | 8, 6 | - | - | 0.4, 13 | 0% | 0% | 55% | 0 | ↑RA | Finland |
| Kobayashi22 | 18 | - | 3.96 | - | 2.6 | - | 2.7 | 39% | 39% | 39% | - | - | Japan |
| Puntmann23 | 24 | 34 | >7.0 | - | 48.3 | 4.7 | >10 | 0% | 0% | 10.5%** | 2.3%** | - | UK, Germany |
| Kobayashi24 | 60 | - | 3.8 | 3 | 7.4 | 1.75 | 11% | 40% | 32% | - | - | Japan | |
*
Data are presented for 31 new RA, 29 established RA starting biologic.
**
LGE assessed globally.
DAS = disease activity score. SJC = swollen joint count. CRP= C-reactive protein. Disease duration presented in median or mean years. TNF= tumor necrosis factor. LGE = late gadolinium enhancement. USA = United States of America. UK = United Kingdom.